

# Curriculum Vitae di

CHIARA NOZZOLI

VIA DELLA ROMOLA 6 SCANDICCI FIRENZE

## ISTRUZIONE E FORMAZIONE

1993 Laurea in Medicina e Chirurgia

1997 Specializzazione in Ematologia

2002 Specializzazione Genetica Medica

2008 Diploma universitario per Corso di Perfezionamento sul Mieloma Multiplo e Gammopatie monoclonali

## Conoscenza Linguistiche

Inglese scritto e parlato di buon livello

## Esperienza lavorativa:

La sottoscritta è dirigente medico della AOU Careggi dal 1 Agosto 2002 attribuita alla SODc Ematologia e dal Marzo 2016 in attività presso SODc terapie cellulari e medicina trasfusionale.

Dal 2002 ha svolto attività assistenziale presso il trapianto di midollo osseo (TMO) sia nella gestione di pazienti riceventi di trapianto di midollo osseo autologo che allogenico, per patologie sia ematologiche che non ematologiche quali malattie autoimmuni. Ha effettuato attività di ricerca e selezione dei donatori non familiari. Dal 2002 ha consolidata esperienza di espanti di midollo osseo per donazione di CSE midollari.

Ha seguito il percorso assistenziale diagnostico-terapeutico di pazienti affetti da Mieloma multiplo sia presso la SODc Ematologia che presso il TMO durante la procedura trapiantologica e nel follow-up post trapiantologico. Ha partecipato attivamente alla gestione multidisciplinare dei pazienti affetti da Mieloma in ambito GOM. Ha partecipato al Gruppo di patologia nazionale (GIMEMA Working party Mieloma) come rappresentante del centro di Firenze Dal 2018 fa parte della commissione trapianto nel mieloma multiplo del GIMEMA. Nel 2018 ha partecipato alla redazione del PDTA su Mieloma multiplo e PDTA per la gestione delle MGUS.

Ha consolidata esperienza come sub-investigatore e/o PI ad oltre 30 studi clinici in GCP. Ha partecipato attivamente alla stesura delle procedure trapiantologiche redatte per accreditamento JACIE del centro trapianti della AOU Careggi. Nel 2017 ha ricevuto incarico professionale di vice direttore SODc terapie cellulari e medicina trasfusionale. E' stata identificata come facilitatore del rischio clinico ed abilitata con specifico corso di formazione aziendale. Dal novembre 2019 è responsabile unità clinica TMO.

## Full papers 2010-2022

1. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. *Blood* 2010; 116: 4745-53.
2. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide versus Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: a randomised controlled trial. *Journal Clin Oncol* 2010;28:2101-9.
3. Offidani M, Leoni P, Corvatta L, et al. Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials. *Clin Lymphoma Myeloma Leu* 2010; 10:353-360.
4. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet* 2010; 376:2075-85.
5. Massi D, Fondi C, Nozzoli C, et al. The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. *Human Pathol* 2011;42:254-68.
6. Messori A, Maratea D, Nozzoli C, Bosi A. The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information. *Pharmacoeconomics* 2011 April; 29:269-285.
7. Cavo M, Palumbo A, Bringhen S, et al. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A

Phase III, Open-Label, Randomized Trial. *Journal Clin Oncol* 2011; Mar 29: 986-93

8. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. *Blood* 2011; 117: 3025-31
9. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M, Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro M, Palumbo A. *Blood*. 2011 Sep 27.
10. The Florence Register of amyloidosis: 20 years' experience in the diagnosis and treatment of the disease in the Florence district area. Cania A, Bergesio F, Curciarello G, Perfetto F, Ciciani AM, Nigrelli S, Minuti B, Caldini AL, Di Lollo S, Nozzoli C, Salvadori M. *Amyloid*. 2011 Jun;18 Suppl 1:81-3
11. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. *Blood*. 2012 Jul 5;120(1):9-19.
12. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, Corradini P. *Biol Blood Marrow Transplant*. 2012 Apr;18(4):617-26.
13. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo

A, Petrucci MT, Patriarca F, Nozzoli C, Cavo M, Offidani M, Florida M, Berretta S, Vallone R, Musto P, Lauria F; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Myeloma Working Party, Marchini E, Fabbri A, Oliva S, Zamagni E, Sapienza FG, Ballanti S, Mele G, Galli M, Pirrotta MT, Di Raimondo F. *Cancer*. 2012 Mar 15;118(6):1574-84. doi: 10.1002/cncr.26447. Epub 2011 Aug 25.

14. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A. *Blood Transfus*. 2013 Jan;11:94-101.
15. Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation. Cesaro S, Pillon M, Tridello G, Aljurf M, Martino R, Schroyens W, Nozzoli C, Barba P, Faraci M, Fagioli F, Cappelli B, Cordonnier C, Al-Mohareb F, Floisand Y, Greil J, Panizzolo IS, Santarone S. *Bone Marrow Transplant*. 2013 Jun;48(6):809-13.
16. Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. Sanz J, Picardi A, Hernández Boluda JC, Martín C, Ferrá C, Nozzoli C, Gonzalez-Vicent M, Rambaldi A, Valcarcel D, Verdeguer A, Serrano D, de Heredia CD, Pascual MJ, de Paz R, Montesinos P, Bartolozzi B, Algarotti A, Sanz MA, Arcese W, Sanz GF; GETH and GITMO. *Biol Blood Marrow Transplant*. 2013 Sep;19(9):1387-92.
17. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Clin Infect Dis*. 2013 Sep;57(6):794-802.

18. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M. . J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
19. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. Nozzoli C<sup>1</sup>, Staderini M, Veltroni A, Longo G, Bacchiari F, Donnini I, Guarrera A, Bosi A. Leuk Lymph 2015 Feb 9:1-4
20. [Free light chains reduction on acute kidney injury in multiple myeloma: critical role of high cut-off membranes Buti E, Dervishi E, Ghiandai G, Mjeshtri A, Paudice N, Terreni A, Caldini A, Nozzoli C, Minetti EE, Bergesio F.G Ital Nefrol. 2014 Nov-Dec;31(6). pii: gin/31.6.11. Italian.
21. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
22. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.Caldini A, Nozzoli C, Terreni A, Staderini M, Berardi M, Biagioli T, Brogi M, Bosi A. Clin Chem Lab Med. 2016 Jun 1;54(6):991-5. doi: 10.1515/cclm-2015-0689
23. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Larocca A, Bringhen S, Petrucci MT, Oliva S, Falcone AP, Caravita T, Villani O, Benevolo G, Liberati AM, Morabito F, Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. Antonioli E, **Nozzoli C**, Buda G, Staderini M, Boncompagni R, Martini F, Petrini M, Bosi A, Saccardi R.Eur J Haematol. 2020 Feb;104(2):138-144. doi: 10.1111/ejh.13357. Epub 2019 Dec 12.
24. Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide. Castellino A, Guidi S, Dellacasa CM, Gozzini A, Donnini I, Nozzoli C, Manetta S, Aydin S, Giaccone L, Festuccia

M, Brunello L, Maffini E, Bruno B, David E, Busca A. *Mediterr J Hematol Infect Dis*. 2018 Jan 1;10(1):e2018001. doi: 10.4084/MJHID.2018.001. eCollection 2018.

25. Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience. Masieri L, Sessa F, Mari A, Campi R, Cito G, Verrienti P, Nozzoli C, Saccardi R, Sforza S, Di Maida F, Grosso AA, Carini M, Minervini A. *Int Urol Nephrol*. 2019 Oct;51(10):1715-1720. doi: 10.1007/s11255-019-02223-0. Epub 2019 Jul 18.
26. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R. *J Hematol Oncol*. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.
27. The doctor who stared at schistocytes: an intriguing case of suspected thrombotic microangiopathic anemia. Pieralli F, Milia A, Fruttuoso S, Bandini G, Mercatelli P, Nozzoli C, Luise F, Mancini A, Sammiceli L, Moggi Pignone A. *Intern Emerg Med*. 2019 Oct 30. doi: 10.1007/s11739-019-02219-9. Online ahead of print. PMID: 31667698
28. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guenec S, Dubin F, Anderson KC; ICARIA-MM study group. *Lancet*. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
29. Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. Antonioli E, **Nozzoli C**, Buda G, Staderini M, Boncompagni R, Martini F, Petrini M, Bosi A, Saccardi R. *Eur J Haematol*. 2020 Feb;104(2):138-144. doi: 10.1111/ejh.13357. Epub 2019 Dec 12.
30. Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience. Antonioli E, Staderini M, Pileri S, Perfetto F, Cappelli F, Allinovi M, Nozzoli C, Attucci I, Buzzichelli A, Messeri M, Bosi A. *Leuk Lymphoma* 2020 Dec;61(13):3255-3258.

31. Toxoplasmosis-Associated Hemophagocytic Lymphohistiocytosis in Allogeneic Transplantation. Cutini I, Gozzini A, Nozzoli C, Boncompagni R, Innocenti C, Fani A, Saccardi R. J Clin Immunol. 2021 May;41(4):843-846. doi: 10.1007/s10875-021-00979-8. Epub 2021 Jan 30.
32. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Zampieri M, Cappelli F, Allinovi M, Olivetto I, Antonioli E, Tassetti L, Zocchi C, Andrei V, Di Mario C, Nozzoli C, Curciarello G, Ciciani AM, Bergesio F, Vannucchi AM, Perfetto F. Amyloid. 2021 Sep;28(3):211-212. Doi 10.1080/13506129.2021.1898365. Epub 2021 Mar 10
33. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. Bonifazi, F., Pavoni, C., Peccatori, J., Giglio, F., Arpinati, M., Busca, A., Bernasconi, P., Grassi, A., Iori, A.P., Patriarca, F., Brunello, L., Di Grazia, C., Carella, A.M., Cilloni, D., Picardi, A., Proia, A., Santarone, S., Sorasio, R., Carluccio, P., Chiusolo, P., Cupri, A., Luppi, M., Nozzoli, C., Baronciani, D., Casini, M., Grillo, G., Musso, M., Onida, F., Palazzo, G., Parma, M., Tringali, S., Vacca, A., Vallisa, D., Sacchi, N., Oldani, E., Masciulli, A., Gheorghiu, A., Girmenia, C., Martino, M., Bruno, B., Rambaldi, A., Ciceri, F., 2022. Bone Marrow Transplantation.. doi:10.1038/s41409-022-01626-5
34. GITMO Registry Study on Allogeneic Transplantation in Patients Aged  $\geq 60$  Years from 2000 to 2017: Improvements and Criticisms. Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, De Gobbi M, Natale A, Terruzzi E, Olivieri A, Chiusolo P, Carella AM, Casini M, Nozzoli C, Mazza P, Bassi S, Onida F, Vacca A, Falcioni S, Luppi M, Iori AP, Pavone V, Skert C, Carluccio P, Borghero C, Proia A, Selleri C, Sacchi N, Mammoliti S, Oldani E, Ciceri F, Russo D, Bonifazi F. Transplant Cell Ther. 2022 Feb;28(2):96.e1-96.e11. doi: 10.1016/j.jtct.2021.11.006. Epub 2021 Nov 21.

Autorizzo il trattamento dei miei dati personali presenti nel curriculum vitae ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 e del GDPR (Regolamento UE 2016/679).

Firma

